PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.68
-0.38 (-1.03%)
At close: 4:00PM EDT

36.55 -0.13 (-0.35%)
Pre-Market: 5:05AM EDT

Stock chart is not supported by your current browser
Previous Close37.06
Open36.92
Bid36.59 x 200
Ask36.73 x 400
Day's Range36.51 - 37.04
52 Week Range31.67 - 39.43
Volume26,309,450
Avg. Volume25,241,191
Market Cap218.194B
Beta0.95
PE Ratio (TTM)10.43
EPS (TTM)3.52
Earnings DateMay 1, 2018
Forward Dividend & Yield1.36 (3.70%)
Ex-Dividend Date2018-02-01
1y Target Est40.11
Trade prices are not sourced from all markets
  • 3 Top Dividend Stocks With Yields Over 3%
    Motley Fool23 minutes ago

    3 Top Dividend Stocks With Yields Over 3%

    A 10-year U.S. Treasury note may yield 3% right now, but we think these stocks are a better investment.

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realist18 hours ago

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realist19 hours ago

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realist19 hours ago

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist21 hours ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist22 hours ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realist23 hours ago

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
    Zacks23 hours ago

    Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

    While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist23 hours ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress
    Market Realist23 hours ago

    Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress

    Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • MarketWatch2 days ago

    Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says

    In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist2 days ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

    The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realist2 days ago

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
    Market Realist2 days ago

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool2 days ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Don't Get Greedy With Novavax, Inc. Stock
    Motley Fool3 days ago

    Don't Get Greedy With Novavax, Inc. Stock

    Novavax's abysmal track record should be a huge red flag for potential shareholders.

  • Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
    Market Realist3 days ago

    Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected

    Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist3 days ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
    Zacks3 days ago

    Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

    Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

  • Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
    Zacks3 days ago

    Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

    Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist3 days ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Reuters3 days ago

    FDA declines to approve Pfizer biosimilar of Roche's cancer drug

    Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist3 days ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.